BCL2 and leukemia: Combining JAK2 inhibitors with BCL-2 inhibitors such as venetoclax could synergistically enhance leukemia cell death by both disrupting survival signaling (via JAK2 inhibition) and promoting apoptosis (via BCL-2 inhibition).